Home > Publications database > Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial. > print

001     291980
005     20250218125235.0
024 7 _ |a 10.1038/s41591-024-03143-y
|2 doi
024 7 _ |a pmid:39054374
|2 pmid
024 7 _ |a 1078-8956
|2 ISSN
024 7 _ |a 1546-170X
|2 ISSN
024 7 _ |a altmetric:165675369
|2 altmetric
037 _ _ |a DKFZ-2024-01563
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hiensch, Anouk E
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial.
260 _ _ |a New York, NY
|c 2024
|b Nature America Inc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1730202495_22133
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C110# / 2024 Oct;30(10):2957-2966
520 _ _ |a Physical exercise both during and after curative cancer treatment has been shown to reduce side effects. Evidence in the metastatic cancer setting is scarce, and interventions that improve health-related quality of life (HRQOL) are much needed for patients with metastatic breast cancer (MBC). The multinational randomized controlled PREFERABLE-EFFECT trial assessed the effects of exercise on fatigue and HRQOL in patients with MBC. In total, 357 patients with MBC and a life expectancy of ≥6 months but without unstable bone metastases were recruited at eight study centers across five European countries and Australia. Participants were randomly assigned (1:1) to usual care (control group, n = 179) or a 9-month supervised exercise program (exercise group, n = 178). Intervention effects on physical fatigue (European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-FA12 scale) and HRQOL (EORTC QLQ-C30 summary score) were determined by comparing the change from baseline to 3, 6 (primary timepoint) and 9 months between groups using mixed models for repeated measures, adjusted for baseline values of the outcome, line of treatment (first or second versus third or higher) and study center. Exercise resulted in significant positive effects on both primary outcomes. Physical fatigue was significantly lower (-5.3 (95% confidence interval (CI), -10.0 to -0.6), Bonferroni-Holm-adjusted P = 0.027; Cohen's effect size, 0.22) and HRQOL significantly higher (4.8 (95% CI, 2.2-7.4), Bonferroni-Holm-adjusted P = 0.0003; effect size, 0.33) in the exercise group than in the control group at 6 months. Two serious adverse events occurred (that is, fractures), but both were not related to bone metastases. These results demonstrate that supervised exercise has positive effects on physical fatigue and HRQOL in patients with MBC and should be recommended as part of supportive care.ClinicalTrials.gov Identifier: NCT04120298 .
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Depenbusch, Johanna
|0 P:(DE-He78)02b45d03ea9bc2c222c7aebf546803c5
|b 1
|e First author
|u dkfz
700 1 _ |a Schmidt, Martina
|0 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
|b 2
|u dkfz
700 1 _ |a Monninkhof, Evelyn M
|b 3
700 1 _ |a Pelaez, Mireia
|b 4
700 1 _ |a Clauss, Dorothea
|b 5
700 1 _ |a Gunasekara, Nadira
|0 0009-0008-5847-7086
|b 6
700 1 _ |a Zimmer, Philipp
|b 7
700 1 _ |a Belloso, Jon
|b 8
700 1 _ |a Trevaskis, Mark
|b 9
700 1 _ |a Rundqvist, Helene
|0 0000-0002-5617-9076
|b 10
700 1 _ |a Wiskemann, Joachim
|b 11
700 1 _ |a Müller, Jana
|b 12
700 1 _ |a Sweegers, Maike G
|0 0000-0003-4892-4061
|b 13
700 1 _ |a Fremd, Carlo
|0 P:(DE-He78)eab4414b2d1a38e0c27a03e1483409bd
|b 14
700 1 _ |a Altena, Renske
|b 15
700 1 _ |a Gorecki, Maciej
|b 16
700 1 _ |a Bijlsma, Rhodé
|b 17
700 1 _ |a van Leeuwen-Snoeks, Lobke
|b 18
700 1 _ |a Ten Bokkel Huinink, Daan
|b 19
700 1 _ |a Sonke, Gabe
|0 0000-0001-8088-9628
|b 20
700 1 _ |a Lahuerta, Ainhara
|b 21
700 1 _ |a Mann, G Bruce
|b 22
700 1 _ |a Francis, Prudence A
|0 0000-0002-7207-9286
|b 23
700 1 _ |a Richardson, Gary
|b 24
700 1 _ |a Malter, Wolfram
|b 25
700 1 _ |a van der Wall, Elsken
|b 26
700 1 _ |a Aaronson, Neil K
|b 27
700 1 _ |a Senkus, Elzbieta
|0 0000-0001-6855-397X
|b 28
700 1 _ |a Urruticoechea, Ander
|b 29
700 1 _ |a Zopf, Eva M
|b 30
700 1 _ |a Bloch, Wilhelm
|b 31
700 1 _ |a Stuiver, Martijn M
|b 32
700 1 _ |a Wengstrom, Yvonne
|0 0000-0001-8317-7829
|b 33
700 1 _ |a Steindorf, Karen
|0 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
|b 34
|u dkfz
700 1 _ |a May, Anne M
|0 0000-0003-0643-3790
|b 35
773 _ _ |a 10.1038/s41591-024-03143-y
|0 PERI:(DE-600)1484517-9
|n 10
|p 2957-2966
|t Nature medicine
|v 30
|y 2024
|x 1078-8956
856 4 _ |u https://inrepo02.dkfz.de/record/291980/files/s41591-024-03143-y.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/291980/files/s41591-024-03143-y.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:291980
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)02b45d03ea9bc2c222c7aebf546803c5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)eab4414b2d1a38e0c27a03e1483409bd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 34
|6 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-29
|w ger
915 _ _ |a DEAL Nature
|0 StatID:(DE-HGF)3003
|2 StatID
|d 2023-08-29
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT MED : 2022
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-29
915 _ _ |a IF >= 80
|0 StatID:(DE-HGF)9980
|2 StatID
|b NAT MED : 2022
|d 2023-08-29
920 1 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
920 0 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C110-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21